IP Library Granted Patent US 9,409,971
Granted Patent B2
US 9,409,971 · App. 14/339,319 · Granted Aug 9, 2016

Method of producing recombinant high molecular weight vWF in cell culture

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,409,971
App. No.
14/339,319
Granted
Aug 9, 2016
Kind
B2
Abstract

Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimeric WF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH 4 + ) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.

Claims (12)

1. A cell culture supernatant comprising recombinant Von Willebrand Factor (rVWF), wherein at least 20% of the rVWF is present in a high molecular weight VWF multimer of more than 10 dimers, wherein the cell culture supernatant has been supplemented to provide a final copper concentration of at least 2.4 μg/L, and wherein the NH 4 + content of the cell culture supernatant is maintained at a concentration below 4 mM or below 10 mM.

2. The cell culture supernatant of claim 1 , wherein the supernatant contains at least 0.5 IU ristocetin cofactor activity per mL.

3. The cell culture supernatant of claim 1 , wherein the supernatant has a rVWF specific ristocetin cofactor activity of at least 30 mU/μg rVWF.

4. The cell culture supernatant of claim 1 , wherein the supernatant has a rVWF specific ristocetin cofactor activity of at least 40 mU/μg rVWF.

5. The cell culture supernatant of claim 1 , wherein the supernatant has a rVWF specific ristocetin cofactor activity of at least 50 mU/μg rVWF.

6. The cell culture supernatant of claim 1 , wherein the supernatant has a rVWF specific ristocetin cofactor activity of at least 60 mU/μg rVWF.

7. The cell culture supernatant of claim 1 , wherein the supernatant has a rVWF specific ristocetin cofactor activity of at least 70 mU/μg rVWF.

8. The cell culture supernatant of claim 1 , wherein the supernatant has a rVWF specific ristocetin cofactor activity of at least 80 mU/μg rVWF.

9. The cell culture supernatant of claim 1 , wherein at least 30% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

10. The cell culture supernatant of claim 1 , wherein the rVWF is present in a high molecular weight VWF multimer of 14 to 22 dimers.

11. The cell culture supernatant of claim 1 , wherein the supernatant further comprises recombinant Factor VIII (rFVIII).

12. The cell culture supernatant of claim 11 , wherein the ratio of rVWF to rFVIII is at least 10:1.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036360/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036376/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2015
From: GRILLBERGER, LEOPOLD; REITER, MANFRED; MUNDT, WOLFGANG
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 035688/0273 →